Revenue up 48% in one quarter is rare for a company this size. Eli Lilly did it in Q2 2026: $23.0B, with full-year guidance raised to $85B to $87B (Q2 results, 5 Aug).
$LLYB , the tokenized Lilly share, opened on Binance Spot on 7 Oct. Its first daily close was $1,189.50 and it closed 10 Oct at $1,179.21. The next fixed date is 29 Oct: the Q3 earnings call at 10:00 am ET, 14:00 UTC (Lilly investor calendar).
The concentration is the risk worth naming. Two drugs, Mounjaro ($9.9B) and Zepbound ($4.9B), made up about 64% of Q2 revenue. A quarter where either one slows would matter more than anything in the pipeline.
The second risk is specific to the token. LLYB swung 4% between its low and high on day one, then traded under $4,000 in total on Saturday 10 Oct (Binance daily data). Around the clock trading does not mean around the clock liquidity.
What would change the picture on 29 Oct: guidance held or raised again with both drugs still growing, or the first quarter where one of them does not.
$LLYB #LLYB #EliLillyRises5.3%ToRecordHigh #BStocks
$LLYB , the tokenized Lilly share, opened on Binance Spot on 7 Oct. Its first daily close was $1,189.50 and it closed 10 Oct at $1,179.21. The next fixed date is 29 Oct: the Q3 earnings call at 10:00 am ET, 14:00 UTC (Lilly investor calendar).
The concentration is the risk worth naming. Two drugs, Mounjaro ($9.9B) and Zepbound ($4.9B), made up about 64% of Q2 revenue. A quarter where either one slows would matter more than anything in the pipeline.
The second risk is specific to the token. LLYB swung 4% between its low and high on day one, then traded under $4,000 in total on Saturday 10 Oct (Binance daily data). Around the clock trading does not mean around the clock liquidity.
What would change the picture on 29 Oct: guidance held or raised again with both drugs still growing, or the first quarter where one of them does not.
$LLYB #LLYB #EliLillyRises5.3%ToRecordHigh #BStocks